128 related articles for article (PubMed ID: 12141739)
1. Prophylactic vaccination against Lyme borreliosis for man and dogs and new strategies to treat established B. burgdorferi infections.
Wallich R; Jahraus O; Simon MM
Int J Med Microbiol; 2002 Jun; 291 Suppl 33():147-9. PubMed ID: 12141739
[No Abstract] [Full Text] [Related]
2. Demonstration of the ability of a canine Lyme vaccine to reduce the incidence of histological synovial lesions following experimentally-induced canine Lyme borreliosis.
Grosenbaugh DA; Rissi DR; Krimer PM
Vet Immunol Immunopathol; 2016 Nov; 180():29-33. PubMed ID: 27692092
[TBL] [Abstract][Full Text] [Related]
3. Protection against tick-transmitted Lyme disease in dogs vaccinated with a multiantigenic vaccine.
Straubinger RK; Dharma Rao T; Davidson E; Summers BA; Jacobson RH; Frey AB
Vaccine; 2001 Oct; 20(1-2):181-93. PubMed ID: 11567763
[TBL] [Abstract][Full Text] [Related]
4. [Lyme borreliosis--vaccines in the "pipeline"].
Kramer M
MMW Fortschr Med; 1999 Jun; 141(25):52-3. PubMed ID: 10897909
[No Abstract] [Full Text] [Related]
5. Immunization with a recombinant subunit OspA vaccine markedly impacts the rate of newly acquired Borrelia burgdorferi infections in client-owned dogs living in a coastal community in Maine, USA.
Eschner AK; Mugnai K
Parasit Vectors; 2015 Feb; 8():92. PubMed ID: 25890386
[TBL] [Abstract][Full Text] [Related]
6. Dogs vaccinated with common Lyme disease vaccines do not respond to IR6, the conserved immunodominant region of the VlsE surface protein of Borrelia burgdorferi.
O'Connor TP; Esty KJ; Hanscom JL; Shields P; Philipp MT
Clin Diagn Lab Immunol; 2004 May; 11(3):458-62. PubMed ID: 15138170
[TBL] [Abstract][Full Text] [Related]
7. Effect of immunization with recombinant OspA on serologic tests for Lyme borreliosis.
Fawcett PT; Rose CD; Budd SM; Gibney KM
Clin Diagn Lab Immunol; 2001 Jan; 8(1):79-84. PubMed ID: 11139199
[TBL] [Abstract][Full Text] [Related]
8. Vaccination against Lyme borreliosis.
Wahlberg P
Ann Med; 1999 Aug; 31(4):233-5. PubMed ID: 10480752
[TBL] [Abstract][Full Text] [Related]
9. More on diagnosis of canine borreliosis.
Sonneborn-Turetsky JH
J Am Vet Med Assoc; 1993 Dec; 203(11):1521-2. PubMed ID: 8288468
[No Abstract] [Full Text] [Related]
10. Vaccination against Lyme disease caused by diverse Borrelia burgdorferi.
Fikrig E; Telford SR; Wallich R; Chen M; Lobet Y; Matuschka FR; Kimsey RB; Kantor FS; Barthold SW; Spielman A; Flavell RA
J Exp Med; 1995 Jan; 181(1):215-21. PubMed ID: 7807004
[TBL] [Abstract][Full Text] [Related]
11. Protection of dogs from Lyme disease with a vaccine containing outer surface protein (Osp) A, OspB, and the saponin adjuvant QS21.
Coughlin RT; Fish D; Mather TN; Ma J; Pavia C; Bulger P
J Infect Dis; 1995 Apr; 171(4):1049-52. PubMed ID: 7706788
[TBL] [Abstract][Full Text] [Related]
12. Borrelia burgdorferi outer surface protein A vaccine: importance, role, and value.
Sigal LH
J Pediatr; 1999 Nov; 135(5):539-41. PubMed ID: 10547238
[No Abstract] [Full Text] [Related]
13. Anti-OspA antibody reduces reservoir competence of mice for Borrelia burgdorferi, the agent of Lyme disease.
Brunet LR; Katavolos P; Spielman A; Telford SR
Med Vet Entomol; 1997 Apr; 11(2):198-200. PubMed ID: 9226653
[No Abstract] [Full Text] [Related]
14. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
[TBL] [Abstract][Full Text] [Related]
15. Vaccination as a modality to prevent Lyme disease. A status report.
Wormser GP
Infect Dis Clin North Am; 1999 Mar; 13(1):135-48, vii. PubMed ID: 10198796
[TBL] [Abstract][Full Text] [Related]
16. Immunization against Lyme disease--an important first step.
Steigbigel RT; Benach JL
N Engl J Med; 1998 Jul; 339(4):263-4. PubMed ID: 9673306
[No Abstract] [Full Text] [Related]
17. Inhibition of Borrelia burgdorferi-tick interactions in vivo by outer surface protein A antibody.
Pal U; Montgomery RR; Lusitani D; Voet P; Weynants V; Malawista SE; Lobet Y; Fikrig E
J Immunol; 2001 Jun; 166(12):7398-403. PubMed ID: 11390491
[TBL] [Abstract][Full Text] [Related]
18. Detection of multiple reactive protein species by immunoblotting after recombinant outer surface protein A lyme disease vaccination.
Molloy PJ; Berardi VP; Persing DH; Sigal LH
Clin Infect Dis; 2000 Jul; 31(1):42-7. PubMed ID: 10913394
[TBL] [Abstract][Full Text] [Related]
19. DNA vaccines expressing a fusion product of outer surface proteins A and C from Borrelia burgdorferi induce protective antibodies suitable for prophylaxis but Not for resolution of Lyme disease.
Wallich R; Siebers A; Jahraus O; Brenner C; Stehle T; Simon MM
Infect Immun; 2001 Apr; 69(4):2130-6. PubMed ID: 11254567
[TBL] [Abstract][Full Text] [Related]
20. Effects of OspA vaccination on Lyme disease serologic testing.
Aguero-Rosenfeld ME; Roberge J; Carbonaro CA; Nowakowski J; Nadelman RB; Wormser GP
J Clin Microbiol; 1999 Nov; 37(11):3718-21. PubMed ID: 10523583
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]